FC
SUPN icon

Financial Consulate’s Supernus Pharmaceuticals SUPN Stock Holding History

Financial Consulate’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$605 Hold
13
– – ﹤0.01% 1284
2026
Q1 		$672 Hold
13
– – ﹤0.01% 1176
2025
Q4 		$647 Hold
13
– – ﹤0.01% 1096
2025
Q3 		$622 Buy
+13
New +$524 ﹤0.01% 943

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Financial Consulate's SUPN Position: Q2 2026 in Review

Financial Consulate held its Supernus Pharmaceuticals (SUPN) position steady in Q2 2026 at 13 shares worth $605. The position accounts for ﹤0.01% of the portfolio, ranked #1284.

Financial Consulate first reported a position in SUPN in Q3 2025 and has held it in 4 quarters since. The position peaked at $672 in Q1 2026. 335 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Financial Consulate held 13 shares of Supernus Pharmaceuticals worth $605 as of Q2 2026.
  • Financial Consulate left its Supernus Pharmaceuticals share count unchanged in Q2 2026.
  • Supernus Pharmaceuticals made up ﹤0.01% of Financial Consulate's portfolio in Q2 2026, its #1284 holding.
  • Financial Consulate first reported a position in Supernus Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Financial Consulate's Supernus Pharmaceuticals position peaked at $672 in Q1 2026.
  • 335 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Financial Consulate's 13F filing for Q2 2026, filed 23 Jul 2026.